

Revenio Group Corporation: Expanding the AI-aided iCare ILLUME screening solution's applications

Revenio Group Corporation, Press release, June 7, 2023 at 4.45 p.m. (EEST)

Revenio Group Corporation: Expanding the AI-aided iCare ILLUME screening solution's applications

In addition to diabetic retinopathy, the AI-aided iCare ILLUME screening is expanded to screen for age-related macular degeneration and glaucoma. The solution supports the early detection of these increasingly common eye diseases.

The iCare ILLUME screening solution instantly detects the signs of sight-threatening diseases with artificial intelligence. The solution, which has received excellent feedback from the markets, was introduced in the spring of 2022 to screen diabetic retinopathy. It can now screen for three common eye diseases: diabetic retinopathy, age-related macular degeneration, and glaucoma.

Age-related eye diseases are becoming more common on a global level. iCare ILLUME screening solution helps detect eye diseases early, thus speeding up the start of treatment. The solution is easy to use, highly accurate, and fully automated. The severity of the eye disease can be seen on the screening report. The screening solution has also been developed to be more flexible regarding the number and used fields of ophthalmic images. The solution is now available in 11 languages.

The iCare ILLUME screening solution supports clinical decision-making for ophthalmic diseases. The accurate data generated by iCare imaging devices and the related software are at the core of the solution. iCare ILLUME combines the images taken with iCare DRSplus retinal imaging system with artificial intelligence, and a screening report is immediately available. After this, a digital referral for a follow-up examination by an ophthalmologist can be made for the patients who need it. This allows for even more extensive utilization of the high-quality images generated by retinal imaging devices to enhance the efficiency of treatment processes.

The comprehensive iCare Solutions includes digital tools to enhance and improve the quality of eye care while enabling the diagnosis and treatment of larger numbers of patients. With digital tools to connect eye care pathways, it is possible to increase productivity and enable high-quality care at the same time.

Pirjo Kortteisto, Business Line Director at Icare Finland, comments: "Eye diseases related to the aging of the population are becoming more common globally, and innovative solutions are needed to increase the efficiency of screening for eye diseases and prevent visual impairments. Our software solutions play an increasingly important role in eye care pathways."

REVENIO

More information about the iCare ILLUME screening solution is available on the website <https://www.icare-world.com/product/icare-illumine/>.

For more information, contact

Pirjo Kortteisto, Business Line Director, Screening
pirjo.kortteisto@icare-world.com

Distribution

Major media
www.reveniogroup.fi/en

Revenio Group in brief

Revenio is a leading company in the global market for ophthalmological devices and software solutions. Revenio's ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters as well as clinical software under the iCare brand. iCare is a trusted partner in ophthalmic diagnostics, offering physicians fast, easy-to-use, and reliable tools for the diagnosis of glaucoma, diabetic retinopathy, and macular degeneration (AMD). iCare Solutions provide digital clinical tools that drive greater efficiency and enhance quality in eye care.

In 2022, the Group's net sales totaled EUR 97.0 million, with an operating profit of EUR 29.7 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.

iCare in brief

iCare is a Finnish company that develops and manufactures innovative hand-held tonometers, fundus imaging devices, perimeters and software solutions for the diagnosis and screening of eye diseases. iCare's vision is to keep the world visible to everyone, and its goal is to facilitate the identification and treatment of eye diseases through its technological solutions. iCare's products are reliable, efficient, and user-friendly, enabling accurate diagnoses to be made at an early stage. iCare collaborates with industry experts and is committed to continually developing new solutions to promote eye health. iCare is part of Helsinki Stock Exchange listed Revenio Group Corporation.

Attachments

[Revenio Group Corporation: Expanding the AI-aided iCare ILLUME screening solution's applications](#)